In a report issued on February 24, Joel Beatty from Robert W. Baird maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price target of $112.00. The company’s shares closed last Friday at $78.00.
According to TipRanks.com, Beatty is a 2-star analyst with an average return of 1.0% and a 42.4% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and Syndax Pharmaceuticals.
Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $113.23, which is a 46.6% upside from current levels. In a report issued on February 24, Truist Financial also reiterated a Buy rating on the stock with a $135.00 price target.
BioMarin Pharmaceutical’s market cap is currently $14.35B and has a P/E ratio of -222.48.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
Read More on BMRN:
- Robert W. Baird Reiterates Their Buy Rating on AdaptHealth (AHCO)
- Leerink Partners Thinks AdaptHealth’s Stock is Going to Recover
- Arcus Biosciences (RCUS) Gets a Buy Rating from Leerink Partners
- Robert W. Baird Sticks to Its Hold Rating for Everbridge (EVBG)
- Leerink Partners Keeps Their Buy Rating on ContraFect (CFRX)